Structural Modelling and Clinical Interpretation of CDKN1B and CDKN2C Variants in Patients with MEN-like Phenotypes: A Case Series
BACKGROUND: Multiple endocrine neoplasia (MEN) syndromes involve tumors in multiple endocrine organs. Distinguishing MEN1 from rarer MEN-like syndromes, including MEN4 caused by pathogenic germline CDKN1B variants, can be challenging. METHODS: We describe four individuals from two families, integrating clinical, biochemical and imaging findings with germline whole-exome sequencing, evolutionary conservation, in silico variant-effect prediction, structural modeling and molecular dynamics. Tumor tissue was unavailable for somatic sequencing or loss-of-heterozygosity analysis. RESULTS: Proband 1, initially suspected of MEN1 because of a nonfunctioning pituitary microadenoma, bilateral adrenal hyperplasia and primary hyperparathyroidism, carried a pathogenic germline CDKN1B frameshift variant, p.Lys96GlnfsTer29. Proband 2 carried the CDKN2C p.Leu107Val variant, classified as a variant of uncertain significance, and had hyperthyroidism, primary hyperaldosteronism, nephrolithiasis, primary hyperparathyroidism, a nonfunctioning pituitary microadenoma and a pancreatic mucinous cystic neoplasm. The variants showed distinct predicted mechanisms. The CDKN1B frameshift preserves the kinase-inhibitory domain but removes the C-terminal regulatory region of p27Kip1 and is predicted to trigger nonsense-mediated decay. In contrast, CDKN2C Leu107 is evolutionarily invariant and buried within the hydrophobic core of ankyrin repeat 4; substitution by valine reduced local hydrophobic packing, consistent with partial destabilization rather than protein loss. The two variant-positive sons of Proband 2 were asymptomatic, and no variant-positive individual carried a MEN1 mutation. CONCLUSIONS: These findings support CDKN1B testing in MEN1-negative patients with MEN features and highlight CDKN2C as a candidate contributor to MEN-like phenotypes. Integrated clinical, genetic, conservation and structural data may support future re-evaluation of p.Leu107Val while preserving its current VUS classification.
Authors
- Amalia Sertedaki (ORCID: https://orcid.org/0000-0002-3648-3812)
- Efthymios Poulios (ORCID: https://orcid.org/0009-0007-0928-9639)
- Dimitriοs Vlachakis (ORCID: https://orcid.org/0000-0003-1823-6102)
- George Panagiotis Chrousos (ORCID: https://orcid.org/0000-0002-3098-5264)
- Nektaria Papadopoulou‐Marketou (ORCID: https://orcid.org/0000-0002-6719-7923)
- Eleni Papakonstantinou (ORCID: https://orcid.org/0000-0002-5189-5508)
- Christina Milou
Institutions
- Agricultural University of Athens (GR)
- UNESCO (FR)
- National and Kapodistrian University of Athens (GR)
- European Neuroendocrine Tumor Society (DE)
- Laiko General Hospital of Athens (GR)
- Children's Hospital Agia Sophia (GR)
- University General Hospital Attikon (GR)
- McGill University (CA)
Publication Details
- Journal
- Endocrine Related Cancer
- Published
- 2026-11-06
- DOI
- https://doi.org/10.1530/erc-26-0093
- Primary Topic
- Genomics and Rare Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00